March 28, 2025 - 00:11

OLD GREENWICH, Conn., March 27, 2025 – Ellington Financial Inc. has disclosed its estimated book value per share of common stock, reporting a value of $13.39 as of February 28, 2025. This figure reflects the company's financial performance and includes the impact of a previously declared monthly dividend.
On March 25, 2025, a dividend of $0.13 per share was paid to shareholders who were on record as of February 28, 2025. The ex-dividend date coincided with this record date, allowing investors to benefit from the dividend payment.
The announcement of the estimated book value is an important indicator for investors, as it provides insight into the company's financial health and asset valuation. As the financial landscape continues to evolve, such updates are crucial for stakeholders to assess their investment strategies and expectations regarding future performance. The company remains committed to transparency and will continue to provide updates on its financial metrics.
May 17, 2026 - 08:31
How Investors Are Reacting To NVE (NVEC) Steady Earnings And Maintained Quarterly DividendNVE Corporation has released its full-year results for the period ending March 31, 2026, posting revenue of US$26.33 million and net income of US$15.2 million. The company also confirmed a...
May 16, 2026 - 22:25
Risky Integration or Rewarding Returns? The Stakes of SoundHound's LivePerson Acquisition.SoundHound AI`s acquisition of LivePerson is drawing mixed reactions from investors, with the immediate fallout hitting the stock price. The deal, which combines SoundHound`s voice AI technology...
May 16, 2026 - 10:38
Bank of Hawaii, Glacier Bancorp, and Wintrust Financial Shares Plummet, What You Need To KnowShares of several regional banks took a sharp hit in afternoon trading Wednesday after the latest inflation report came in hotter than expected. The April Consumer Price Index rose 3.8%, a figure...
May 15, 2026 - 17:39
Plus Therapeutics Shares First Quarter 2026 Financial Results and Updates on REYOBIQ and CNSide ProgressHOUSTON, May 15, 2026 -- Plus Therapeutics, a healthcare company focused on precision diagnostics and radiopharmaceuticals for central nervous system cancers, reported its financial results for the...